



an Open Access Journal by MDPI

## State-of-the-Art Drug Metabolism in Europe

Guest Editors:

**Dr. Ewelina Dziurkowska**

Department of Analytical  
Chemistry, Medical University of  
Gdansk, Gen. J. Hallera 107, 80-  
416 Gdansk, Poland

**Prof. Dr. Marek Wesółowski**

Department of Analytical  
Chemistry, Medical University of  
Gdansk, Gen. J. Hallera 107, 80-  
416 Gdansk, Poland

Deadline for manuscript  
submissions:

**closed (31 December 2023)**

### Message from the Guest Editors

Dear Colleagues,

The aim of this Special Issue is to publish articles addressing State-of-the-Art Drug Metabolism in Europe.

Metabolism is one of the most important processes in the body. It enables the body to produce energy, but also to convert exogenous substances such as drugs into compounds that can be removed. A patient's health status, polytherapy, as well as genetic factors have a significant impact on the rate of drug metabolism.

Therefore, this Special Issue is devoted to drug metabolism in a wide sense, including how genetic changes, hormonal changes, patient health status or additionally ingested compounds affect metabolic rate. Other topics of interest include analytical methods used to determine metabolites and parent compounds, as well as the selection of biological matrices for determining the concentration of analytes in the body and the determination of procedures that should be followed in order to make the determination of compounds reliable.

Dr. Ewelina Dziurkowska  
Prof. Dr. Marek Wesółowski  
*Guest Editors*



[mdpi.com/si/120571](https://mdpi.com/si/120571)



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI